Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05996185 · ClinicalTrials.gov registry record · Phase 2
Study of Mogamulizumab With DA-EPOCH or CHOEP in Patients With Aggressive T-cell Lymphoma
A Phase 2 study of T-Cell Lymphoma, sponsored by Yale University.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 22
- Enrollment target
- 2
- Study locations
NCT05996185 is a Phase 2 study of T-Cell Lymphoma that is actively recruiting participants, run by Yale University. The registered enrollment target is 22 participants, below the 133-participant average among 15 other T-Cell Lymphoma trials with a reported enrollment target (83% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT05996185, a Phase 2 study of T-Cell Lymphoma, is actively recruiting participants, sponsored by Yale University.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 22 participants
- Enrollment target
- 2
- Study locations
Study Summary
Single-arm Phase II study evaluating the combination of mogamulizumab (MOGA) added on top of standard of care dose adjusted EPOCH (DA-EPOCH) or CHOEP in patients with newly diagnosed or relapsed/refractory (for CTCL only) aggressive T-cell lymphoma including patients with Adult T-cell leukemia/lymphoma (ATLL).
Conditions Studied
Interventions
- DRUG Mogamulizumab
- DRUG DA-EPOCH Protocol
- DRUG CHOEP protocol
Study Locations (2)
Connecticut
- Yale Cancer Center, Clinical Trials Office - New Haven
New York
- Icahn School of Medicine at Mount Sinai - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2024-10-09 |
| Est. Completion | 2027-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05996185
The ClinicalTrials.gov registry entry for NCT05996185 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 133-participant average among 15 other T-Cell Lymphoma trials with a reported enrollment target (83% lower). The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with T-Cell Lymphoma appearing as the primary indexed condition, and to 3 interventions - of which Mogamulizumab is the first listed.
NCT05996185 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Connecticut, New York.
Frequently Asked Questions
What is clinical trial NCT05996185 about?
NCT05996185 is a clinical study titled "Study of Mogamulizumab With DA-EPOCH or CHOEP in Patients With Aggressive T-cell Lymphoma". Single-arm Phase II study evaluating the combination of mogamulizumab (MOGA) added on top of standard of care dose adjusted EPOCH (DA-EPOCH) or CHOEP in patients with newly diagnosed or relapsed/refractory (for CTCL only) aggressive T-cell lymphoma including patients with Adult T-cell leukemia/lymph...
What is the current status of trial NCT05996185?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 22 participants. The study started on 2024-10-09. Estimated completion is 2027-11.
What conditions does trial NCT05996185 study?
This clinical trial studies the following conditions: T-Cell Lymphoma.
What interventions are being tested in trial NCT05996185?
The interventions under investigation include: Mogamulizumab (DRUG), DA-EPOCH Protocol (DRUG), CHOEP protocol (DRUG).
Who is sponsoring clinical trial NCT05996185?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05996185 being conducted?
This trial has 2 study locations across Connecticut, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for T-Cell Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Pembrolizumab and Brentuximab Vedotin in Subjects With Relapsed/Refractory T-cell Lymphoma
RECRUITING · Phase 2
-
Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL)
RECRUITING · Phase 2
-
Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell Lymphoma
RECRUITING · Phase 2
-
A Study of Enasidenib in People With T-Cell Lymphoma
RECRUITING · Phase 2
-
Duvelisib Maintenance After Autologous Stem Cell Transplant in T-Cell Lymphomas
ACTIVE NOT RECRUITING · Phase 2
-
Total Body Irradiation +/- Total Lymphoid Irradiation & Anti-Thymocyte Globulin in Non-myeloablative Hematopoietic Cell Transplantation
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.